RVL Pharmaceuticals plc (NASDAQ:RVLP) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET
Company Participants
Lisa Wilson - In-Site Communications, IR
Brian Markison - Chief Executive Officer
James Schaub - Chief Operating Officer
Michael DePetris - Principal Accounting Officer
Conference Call Participants
Douglas Tsao - H.C. Wainright
John Vandermosten - Zacks SCR
Glen Santangelo - Jefferies
Operator
Good day, and thank you for standing by. Welcome to the RVL Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your host today, Lisa Wilson, Investor Relations for RVL. Please go ahead.
Lisa Wilson
Thank you, operator. Welcome to RVL Pharmaceuticals second quarter 2023 financial results and commercial update call. This is Lisa Wilson, Investor Relations for RVL. With me on today's call are RBL's Chief Executive Officer, Brian Markison; Chief Operating Officer, JD Schaub; and Principal Accounting Officer, Mike DePetris. This morning, the Company issued a press release detailing financial results for the three months ended June 30, 2023. This press release and a webcast of this call can be accessed through the Investors section of the RVL website @rvlpharma.com.
Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the Company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act.
These forward looking statements are based on information available to RBL's management as of today. Involve risks and uncertainties, including those noted in today's press release and the Company's filings with the Securities and Exchange Commission. Such forward looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. RVL specifically disclaims any intent or obligation to update these forward-looking statements, except as required by law.
During this call, we refer to non-GAAP financial measures, such as adjusted EBITDA loss. For a reconciliation of adjusted EBITDA loss to net loss, please see the tables at the end of today's press release. The archived webcast of this call will be available for one year on RVL's website, rvlpharma.com. For the benefit of those who may be listening to the replay or archived webcast, this call is held and recorded on Monday, August 14, 2022. Since then, RVL may have made announcements related to the topics discussed, so please reference the Company's most recent press releases and SEC filings.